Charles River Laboratories Intl. Inc (NYSE:CRL) was the recipient of a significant decrease in short interest in December. As of December 31st, there was short interest totalling 976,900 shares, a decrease of 7.8% from the December 15th total of 1,060,000 shares. Approximately 2.0% of the shares of the company are sold short. Based on an average trading volume of 310,100 shares, the days-to-cover ratio is presently 3.2 days.

Shares of NYSE:CRL traded down $0.77 on Wednesday, hitting $158.84. The company had a trading volume of 364,938 shares, compared to its average volume of 344,600. Charles River Laboratories Intl. has a 1-year low of $115.69 and a 1-year high of $161.39. The stock has a market cap of $7.80 billion, a price-to-earnings ratio of 26.34, a P/E/G ratio of 1.78 and a beta of 1.11. The stock has a 50 day moving average price of $150.39 and a 200 day moving average price of $138.12. The company has a current ratio of 1.43, a quick ratio of 1.20 and a debt-to-equity ratio of 1.30.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 6th. The medical research company reported $1.69 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.64 by $0.05. Charles River Laboratories Intl. had a net margin of 9.14% and a return on equity of 21.52%. The business had revenue of $668.00 million for the quarter, compared to the consensus estimate of $674.08 million. During the same period in the prior year, the company posted $1.53 earnings per share. Charles River Laboratories Intl.’s revenue was up 14.1% compared to the same quarter last year. Sell-side analysts anticipate that Charles River Laboratories Intl. will post 6.55 earnings per share for the current fiscal year.

Several equities analysts have commented on CRL shares. Argus reiterated a “buy” rating and issued a $170.00 price objective on shares of Charles River Laboratories Intl. in a report on Tuesday, November 19th. KeyCorp upped their price objective on shares of Charles River Laboratories Intl. from $151.00 to $162.00 and gave the company an “overweight” rating in a report on Monday, December 9th. Bank of America downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 price objective on the stock. in a report on Friday, October 18th. Citigroup started coverage on shares of Charles River Laboratories Intl. in a report on Monday, January 6th. They issued a “buy” rating and a $185.00 price objective on the stock. Finally, Robert W. Baird upped their price objective on shares of Charles River Laboratories Intl. from $160.00 to $165.00 and gave the company an “outperform” rating in a report on Tuesday, December 17th. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $163.29.

In other Charles River Laboratories Intl. news, VP Birgit Girshick sold 1,051 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $145.55, for a total transaction of $152,973.05. Following the sale, the vice president now directly owns 18,728 shares of the company’s stock, valued at $2,725,860.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.80% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. Tocqueville Asset Management L.P. acquired a new position in shares of Charles River Laboratories Intl. in the fourth quarter valued at about $367,000. Trinity Street Asset Management LLP grew its stake in shares of Charles River Laboratories Intl. by 3.8% in the fourth quarter. Trinity Street Asset Management LLP now owns 192,869 shares of the medical research company’s stock valued at $29,462,000 after acquiring an additional 7,094 shares in the last quarter. Boston Trust Walden Corp grew its stake in shares of Charles River Laboratories Intl. by 1.2% in the fourth quarter. Boston Trust Walden Corp now owns 146,542 shares of the medical research company’s stock valued at $22,385,000 after acquiring an additional 1,791 shares in the last quarter. Metropolitan Life Insurance Co NY grew its stake in shares of Charles River Laboratories Intl. by 2.6% in the third quarter. Metropolitan Life Insurance Co NY now owns 15,988 shares of the medical research company’s stock valued at $2,116,000 after acquiring an additional 408 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in shares of Charles River Laboratories Intl. by 2,284.6% in the third quarter. Point72 Asset Management L.P. now owns 11,923 shares of the medical research company’s stock valued at $1,578,000 after acquiring an additional 11,423 shares in the last quarter. Institutional investors and hedge funds own 95.80% of the company’s stock.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: What is a stock portfolio tracker?

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.